// App-Quantinova.ai

P501 : Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)

Researchers

Presenter

  • C.A. Siegel

Principal Investigators

  • B. Siegmund

  • J.D. Lewis

  • D. Wolf

  • E. Louis

  • S. Sebastian

  • X. Hebuterne

  • A. Bell

  • C. Sderman

  • S. Schubert

  • R. Atreya

  • S. Polyak

  • S. Hoque

  • A. Krummenerl

  • B. Bokemeyer

  • T. Krummenerl

  • S. Shulmann

  • P. Karln

  • B. Moum

  • P. Dolin

Medical Centers

  • Dartmouth-Hitchcock Medical Center, Gastroenterology, Lebanon, United States

  • University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

  • Charite - University Medicine Berlin, Campus Benjamin Franklin, Deptartment of Neurology, Berlin, Germany

  • Atlanta Gastroenterology Associates, Atlanta, Georgia, United States

  • CHU Liege, Liege, Belgium

  • Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom

  • CHU de Lille, Department of Gastroenterology, Lille, France

  • Weston General Hospital, Weston Area Health Trust - Department of Gastroenterology, Weston Super Mare, United Kingdom

  • St Goeran Hospital, Stockholm, Sweden

  • Praxis für Gastroenterologie, Heidelberg, Germany

  • University Hospital of Ulm, Department of Urology, Ulm, Germany

  • University of Iowa Health Care, Inflammatory Bowel Diseases & Celiac Disease Center, Iowa City, United States

  • St George's NHS Trust, Gastroenterology, London, United Kingdom

  • Hospital Martha-Maria Halle-Doelau, Halle, Germany

  • Gastroenterologische Gemeinschaftspraxis, Gastroenterology, Minden, Germany

  • Gastroenterologische Gemeinschaftspraxis am Germania-Campus, Muenster, Germany

  • Scott Shulman Medical, North Bay, Ontanio, Canada

  • Ersta Hospital, Department of Gastroenterology, Stockholm, Sweden

  • Oslo University, Department of Gastroenterology, Oslo, Norway

  • Takeda Development Centre Europe, Pharmacoepidemiology, London, United Kingdom

Locations

  • United States

  • Germany

  • Belgium

  • United Kingdom

  • France

  • Sweden

  • Canada

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • N/A


Study Design

  • Observational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A